This document is an excerpt from the EUR-Lex website
Document 52018M9160
Prior notification of a concentration (Case M.9160 — Centerbridge/Hospital Topco) — Candidate case for simplified procedure (Text with EEA relevance.)
Prior notification of a concentration (Case M.9160 — Centerbridge/Hospital Topco) — Candidate case for simplified procedure (Text with EEA relevance.)
Prior notification of a concentration (Case M.9160 — Centerbridge/Hospital Topco) — Candidate case for simplified procedure (Text with EEA relevance.)
IO C 401, 7.11.2018, p. 12–12
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
7.11.2018 |
EN |
Official Journal of the European Union |
C 401/12 |
Prior notification of a concentration
(Case M.9160 — Centerbridge/Hospital Topco)
Candidate case for simplified procedure
(Text with EEA relevance)
(2018/C 401/10)
1.
On 29 October 2018, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).This notification concerns the following undertakings:
|
— |
Centerbridge Partners, L.P. (‘Centerbridge’, United States of America), |
|
— |
Hospital Topco Limited (‘Hospital Topco’, United Kingdom). |
Centerbridge acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Hospital Topco.
The concentration is accomplished by way of purchase of shares.
2.
The business activities of the undertakings concerned are:— for Centerbridge: investment management firm focused on private equity and distressed investment opportunities,
— for Hospital Topco: parent company of the healthcare group that carries out its operations under the BMI Healthcare brand, and the property interest holding companies.
3.
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.
4.
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.9160 — Centerbridge/Hospital Topco
Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:
|
Email: COMP-MERGER-REGISTRY@ec.europa.eu |
|
Fax +32 22964301 |
|
Postal address: |
|
European Commission |
|
Directorate-General for Competition |
|
Merger Registry |
|
1049 Bruxelles/Brussel |
|
BELGIQUE/BELGIË |
(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).